4BIO Capital Portfolio Company Entact Bio Launches with $81 Million Series A

SparingVision’s lead asset SPVN06 clears IND application in the US for retinitis pigmentosa

4BIO Capital Portfolio Company Redpin Therapeutics to be Acquired by Kriya Therapeutics

Araris Biotech Closes $24 Million Financing Round

4BIO Capital Portfolio Company Carisma Therapeutics and Sesen Bio Announce Merger Agreement

SparingVision Raises €75 Million Series B